Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer With Onapristone
11/9/2012 11:25:05 AM
FLEMINGTON, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc. (OTCBB: ARNI) today reported progress in its clinical biomarker program to develop a companion diagnostic with onapristone in the treatment of breast and other cancers. Onapristone is the company’s investigational progestin receptor antagonist that has demonstrated anti-tumor activity in preclinical and clinical studies of hormone-dependent tumors.
comments powered by